1WorldSync — FDA/GUDID publishing via partner workflow
Cruxi Inc.
Cruxi offers AI-powered regulatory submission services for medical devices, streamlining processes like FDA 510(k), De Novo, and PMA. They provide expert guidance and automated compliance checks.
Cruxi provides a comprehensive, AI-powered platform designed to simplify medical device regulatory submissions. Their services cover a wide range of FDA and global market needs, including FDA 510(k), De Novo Classification Requests (eSTAR), Q-Submissions, and PMA Supplements. Leveraging intelligent automation and expert guidance, Cruxi aims to streamline the entire submission workflow, from device classification to the final package, ensuring automated compliance checks at every step. They offer specialized solutions for traditional 510(k) submissions, which typically have a 90-day FDA review period. For novel, low to moderate-risk devices, Cruxi supports the mandatory eSTAR use starting October 1, 2025. Additionally, their platform facilitates formal device classification determinations and supports 180-day, Real-Time supplements with repeatable templates and checklists, making regulatory processes more efficient and manageable for manufacturers.
About
1WorldSync — FDA/GUDID publishing via partner workflow is a provider focused on streamlining regulatory submissions for medical devices. They offer services specifically designed to facilitate FDA GUDID submissions through a partner workflow, aiming to simplify the process for manufacturers. Their expertise lies in navigating the complexities of regulatory data management and submission requirements.
- **Who they are** 1WorldSync — FDA/GUDID publishing via partner workflow assists companies in managing their regulatory data and submissions, particularly for the FDA's Global Unique Device Identification Database (GUDID).
- **Expertise & scope** * Facilitates FDA GUDID submissions via a partner workflow. * Focuses on streamlining the publishing of device identification data.
- **Reputation / proof points** * Languages: English
Additional information
For buyers utilizing 1WorldSync — FDA/GUDID publishing via partner workflow, understanding the submission process is key. The service is designed to integrate with existing partner workflows, suggesting a need for clear data mapping and internal process alignment before engagement. Buyers should anticipate a focus on accurate and timely data publication to meet FDA requirements. The primary language of operation and support is English.
Key Highlights
Supports FDA/GUDID publishing via a partner workflow.
Source